Collectively, our present study identified the novel molecular mechanism behind CBFB regulation and its indispensable roles in tumorigenesis, which provides an insight into understanding how AML cells could become resistant to RUNX1-inhibition therapy (Fig. 7). Here, CBFB is linked to acute myeloid leukemia.